Zobrazeno 1 - 10
of 10
pro vyhledávání: '"K. J. Resser"'
Autor:
A. Rozanski, C. N. Bairey, D. S. Krantz, J. Friedman, K. J. Resser, M. Morell, S. Hilton-Chalfen, L. Hestrin, J. Bietendorf, D. S. Berman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43f6b08de5db251c2e9abd7b802c47a4
https://doi.org/10.1017/cbo9780511759048.012
https://doi.org/10.1017/cbo9780511759048.012
Publikováno v:
Cancer. 56(10)
Eighty-one patients with advanced testicular cancer were evaluated for gynecomastia or severe breast tenderness at diagnosis and after platinum-based chemotherapy. The prognostic significance of gynecomastia in these two settings was explored. At pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d47073f341345966c878a4f5bb786453
https://pubmed.ncbi.nlm.nih.gov/4042075
https://pubmed.ncbi.nlm.nih.gov/4042075
Publikováno v:
Cancer treatment reports. 66(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5f40adab079df4dc36d24c96225227ec
https://pubmed.ncbi.nlm.nih.gov/7083225
https://pubmed.ncbi.nlm.nih.gov/7083225
Publikováno v:
Cancer treatment reports. 63(11-12)
Thirteen patients with hepatocellular cancer were treated with intrahepatic arterial Adriamycin and 5-fluorouracil combined with whole-liver irradiation. Six patients (46%) had an objective regression and five (38%) had stable disease. Symptomatic im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4e2c66e710660a6fd413191cce2cf239
https://pubmed.ncbi.nlm.nih.gov/230895
https://pubmed.ncbi.nlm.nih.gov/230895
Publikováno v:
Cancer treatment reports. 68(7-8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ecbab85d5a4871faa1013576ef935d3e
https://pubmed.ncbi.nlm.nih.gov/6744348
https://pubmed.ncbi.nlm.nih.gov/6744348
Publikováno v:
Cancer. 44(3)
Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f75d34f83f3bd829b189002175b362b
https://pubmed.ncbi.nlm.nih.gov/113078
https://pubmed.ncbi.nlm.nih.gov/113078
Autor:
M A, Friedman, D A, Kaufman, J E, Williams, K J, Resser, E H, Rosenbaum, R J, Cohen, A B, Glassberg, M R, Blume, J, Gershow, E Y, Chan
Publikováno v:
Cancer treatment reports. 63(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::65b3279a0bd9ddecd823e2229ab982c2
https://pubmed.ncbi.nlm.nih.gov/371802
https://pubmed.ncbi.nlm.nih.gov/371802
Publikováno v:
Annals of the Academy of Medicine, Singapore. 9(2)
Hepatocellular cancer provides an ideal model for studying combined modality chemotherapy and radiation interactions. We have treated 20 evaluable patients. All patients received intrahepatic arterial (IA) 5 FU (10 mg/kg/d continuous infusion times 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aee52b4de10aecd93a5a1a42acdc8b30
https://pubmed.ncbi.nlm.nih.gov/6252817
https://pubmed.ncbi.nlm.nih.gov/6252817
Autor:
M A, Friedman, F S, Marcus, M J, Cassidy, K J, Resser, M, Kohler, C G, Hendrickson, R, Reynolds, D, Johnson, T, Kilbridge, K, Yu, M, Cruicitt
Publikováno v:
Cancer. 52(2)
One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM). The objective response rate for 82 evaluable patients whose disease was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c97eae311dcf0584fefb32997725733a
https://pubmed.ncbi.nlm.nih.gov/6344976
https://pubmed.ncbi.nlm.nih.gov/6344976
Autor:
V A, Levin, W M, Wara, R L, Davis, P, Silver, K J, Resser, K, Yatsko, S, Nutik, P H, Gutin, C B, Wilson
Publikováno v:
Cancer treatment reports. 70(6)
The Northern California Oncology Group (NCOG) conducted a nonrandomized phase II study to evaluate the benefit of a seven-drug chemotherapy protocol (NCOG 6G91) in patients with glioblastoma multiforme (GM). Time to tumor progression was the primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da3884083f068f09ed60bc79c1064881
https://pubmed.ncbi.nlm.nih.gov/3015402
https://pubmed.ncbi.nlm.nih.gov/3015402